CureVac (NASDAQ:CVAC) Shares Acquired by Ballentine Partners LLC

Ballentine Partners LLC increased its stake in CureVac (NASDAQ:CVAC) by 58.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,755 shares of the company’s stock after acquiring an additional 8,406 shares during the period. Ballentine Partners LLC’s holdings in CureVac were worth $67,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Private Advisor Group LLC acquired a new stake in shares of CureVac in the third quarter worth approximately $30,000. International Assets Investment Management LLC acquired a new position in CureVac during the third quarter valued at approximately $35,000. Bank of New York Mellon Corp acquired a new position in CureVac during the second quarter valued at approximately $54,000. Signaturefd LLC lifted its position in CureVac by 232.0% during the second quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after buying an additional 15,403 shares in the last quarter. Finally, Green Alpha Advisors LLC lifted its position in CureVac by 41.3% during the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock valued at $80,000 after buying an additional 7,979 shares in the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Trading Down 3.1 %

Shares of CVAC stock opened at $2.80 on Thursday. The firm’s 50 day moving average price is $3.01 and its two-hundred day moving average price is $3.24. CureVac has a fifty-two week low of $2.21 and a fifty-two week high of $6.30. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market cap of $626.86 million, a price-to-earnings ratio of -2.09, a price-to-earnings-growth ratio of 2.07 and a beta of 2.62.

CureVac (NASDAQ:CVAC) last posted its earnings results on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The firm had revenue of $15.55 million for the quarter, compared to analyst estimates of $10.07 million. On average, analysts anticipate that CureVac will post 0.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price target on shares of CureVac in a research report on Monday, September 16th.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.